文章来自Maiwald博客
Determining the value in dispute in patent nullity proceedings if the pharmaceutical product in question does not make use of the teaching of the contested patent – Value in Dispute V
In nullity appeal proceedings, on the application of the appellant the Federal Court of Justice ruled on 23 January 2024 (case no. X ZR 161/23 - not published yet) to signific...
Continue reading
Decision on inventive step casts new light on EBA’s ‘plausibility’ guidance: T 0116/18 and a review after 10 months of G 2/21
In March last year, the much-awaited decision of the Enlarged Board of Appeal (EBA), G 2/21, issued on the topic of “plausibility”, a catchword much appli...
Continue reading
Paris, Munich, Milan – first revision of the UPCA adopted
It has been agreed upon for several weeks and was already confirmed at the meeting of the Administrative Committee of the Unified Patent Court (UPC)
Continue reading
Maiwald is pleased to be a member of the UPCLA network
What is the UPCLA network? The UPCLA network, created in 2014, is a non-exclusive network of European law...
Continue reading
To use or not to use – the nuisance of repeated trademark filings
The so-called grace period for use in the EU Trademark Regulation is intended to give applicants the opportunity to protect their trademark and thus an important marketing too...
Continue reading
News on EU Pharmaceutical and Medical Devices Laws
1. New pharmaceutical legislation With the so-called
Continue reading
